You are here

TCT 2017

Sunday, October 29, 2017 to Thursday, November 2, 2017

Latest Headlines

 - treadmill

During the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Michael J. Rinaldi, MD, showed a survey of 92 health systems in which 52 percent reported an average negative margin on TAVR procedures. In an hour-long session, Rinaldi and other experts agreed shortening hospital stays and reducing the number of days spent in the intensive care unit (ICU) are key aspects in making TAVR more profitable for hospitals.

 - Herbert Aronow

Herbert D. Aronow, MD, MPH, discussed with Cardiovascular Business how to align financial incentives between physicians, hospital administrators and other stakeholders, and how collaboration could lead to success under MACRA.

 - CorPath GRX robotic system

Recent studies have shown robotic PCI to be a feasible way to treat coronary artery disease. But at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference Oct. 30, Ryan D. Madder, MD, took the conversation a step further: Will it eventually be possible to perform “tele-stenting” over long distances?

 - FFR

Research presented Nov. 2 at the Transcatheter Cardiovascular Therapeutics scientific symposium in Denver demonstrates patients with stable coronary artery disease (CAD) and abnormal fractional flow reserve (FFR) derive better clinical outcomes with PCI at similar cost to medical therapy alone.

 - going to surgery

An image-guided cardiac device designed to repair the mitral valve while a patient’s heart is still beating could provide a safe, effective alternative to traditional open heart surgery, according to research presented Nov. 1 at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Denver.

 - TCT 17

Differences in exercise duration for patients with stable angina who received either PCI or a placebo treatment were not statistically significant, according to research presented Nov. 2 at the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium and published simultaneously in The Lancet.

 - watchman.png

A meta-analysis of the PREVAIL and PROTECT AF trials, two studies aimed at evaluating the efficacy of left atrial appendage closure (LAAC) with the Watchman device in atrial fibrillation (AFib) patients, ultimately found that LAAC with Watchman provides stroke prevention for nonvalvular AFib patients comparable to warfarin, with additional decreases in major bleeding events and mortality. The 5-year findings were presented at the 29th annual Transcatheter Cardiovascular Therapeutics convention in Denver.

Transcatheter mitral valve replacement (TMVR) using a new self-expanding, tri-leaflet bovine valve was a success in the majority of patients enrolled in a pioneering global study, according to data presented this week at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in Denver.

 - Heart

Six months of dual antiplatelet therapy (DAPT) was found to be non-inferior in ST-elevation myocardial infarction (STEMI) patients to the internationally recommended 12-month regimen in a pioneering trial presented at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Denver.

 - MoneyBags

DENVER — Transcatheter aortic valve replacement (TAVR) is an “economically dominant” strategy compared to surgical aortic valve replacement (SAVR) for patients with aortic stenosis at intermediate surgical risk, according to data presented by David J. Cohen, MD, MSc, Oct. 31 at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.